SCHEMBL1922346

SCHEMBL1922346

CCOC(=O)c1c(CC)nn2c(-c3ccc(Cl)cc3Cl)c(C)oc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.46
TSHR P16473 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HSD17B10 Q99714 2/20 0.46
NPC1 O15118 1/20 0.46
POLB P06746 1/20 0.46
RAB9A P51151 1/20 0.46
KDM4E B2RXH2 4/20 0.43
DPP4 P27487 2/20 0.43
DPP8 Q6V1X1 1/20 0.43
DPP9 Q86TI2 1/20 0.43
CDC7 O00311 1/20 0.39
DBF4 Q9UBU7 1/20 0.39
LMNA P02545 3/20 0.38
KMT2A Q03164 2/20 0.38
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38
CNR1 P21554 1/20 0.38
ALDH1A1 P00352 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1922183 0.89 MARS1 (0.40) MAPTTSHRSMN1; SMN2HSD17B10NPC1
SCHEMBL1922326 0.83 NPC1 (0.45) MAPTTSHRSMN1; SMN2NPC1RAB9A
SCHEMBL1922608 0.82 NPC1 (0.46) MAPTTSHRSMN1; SMN2NPC1RAB9A
SCHEMBL1922932 0.82 SMN1; SMN2 (0.48) MAPTTSHRSMN1; SMN2NPC1RAB9A
SCHEMBL1922248 0.81 GPBAR1 (0.45) TSHRSMN1; SMN2DPP4DPP8DPP9
SCHEMBL1922987 0.80 DPP4 (0.38) MAPTTSHRSMN1; SMN2HSD17B10NPC1
SCHEMBL1922628 0.80 DPP4 (0.42) SMN1; SMN2POLBDPP4DPP8DPP9
SCHEMBL2260849 0.79 DPP4 (0.41) DPP4DPP8DPP9
SCHEMBL2255880 0.79 CRHR1 (0.40) DPP4DPP8KMT2A
SCHEMBL2256320 0.79 CRHR1 (0.40) MAPTTSHRSMN1; SMN2HSD17B10NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 US disclosed
EP-2328902-A1 PYRAZOLO [5,1-B]OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS Novartis AG (CH) 2011-06-08 EP disclosed
WO-2010015628-A1 PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS NOVARTIS AG (CH) 2010-02-11 WO disclosed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035874-A1 Organic compounds CRH, CRHR1, CRHR2 MAPT 2511/4885TSHR 297/4885SMN1; SMN2 3864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.